Staging, therapy and prognosis of primary @entity1893 's XXXX and a comparison of results with localized @entity2828 : ten years experience at the Istituto Ortopedico Rizzoli.

@entity632 @entity1 @entity2828 @entity706 @entity5 @entity786 @entity1891 @entity1893
Thirty consecutive cases of localized primary @entity1893 's @entity706 (PNHLB) were treated in a 10-year period at the Istituto Ortopedico Rizzoli with localized radiation (4 cases) and localized radiation and adjuvant chemotherapy (26 cases). The doses of radiation varied from 3000-4500 rad. A variety of staging procedures evolving with new diagnostic techniques over the 10 years were performed. Adjuvant chemotherapy comprised two different regimens of @entity1891 , @entity632 and @entity786 . Twenty-four of the 26 @entity1 (92%) have been free of disease with a median follow-up of 75.5 months (18-144 months). Two @entity1 developed meningeal involvement and one @entity1 , treated with radiation therapy only, developed a local recurrence. The results are compared to the management of 68 @entity2828 @entity1 treated during the same period. Here, higher doses of localized radiation therapy (approximately 5000 rad) and similar adjuvant chemotherapy were administered. The survival was 32% (22/68) with a higher incidence of local recurrence (21%). These data indicate that PNHLB should be considered a separate entity from @entity2828 and can be treated successfully with lower doses of radiation to the @entity5 and adjuvant chemotherapy. The observations are also compared to a variety of other biological characteristics of @entity2828 . Since only two @entity1 developed meningeal relapse, our experience does not permit a firm recommendation for routine prophylactic treatment of the central nervous system in PNHLB.
